38 Healthcare Deals, One Pattern: Pharma Buys, AI Startups Raise, and the Middle Disappears

Thirty-eight healthcare deals crossed the wire in the last nine days. Together, they represent roughly $4 billion in capital. But that number is misleading—because $3.1 billion of it came from just two transactions.

Novartis paid $2 billion for Synnovation Therapeutics' PI3Kα inhibitor program. QHP Capital closed a $1.1 billion continuation fund for Azurity Pharmaceuticals. Strip those out, and the remaining 36 deals split roughly $900 million—an average of $25 million each.

That split tells the real story of healthcare dealmaking right now: massive pharma M&A at the top, a growing cluster of AI-enabled startups at the bottom, and an increasingly thin middle.

Big Pharma Is Still the Biggest Buyer

Biotech and pharma accounted for 13 of the 38 deals but absorbed 86% of total capital. The Novartis acquisition stands out not just for its size but for its specificity—a single drug program, not a platform company. That kind of targeted M&A, where large pharma acquires clinical-stage assets rather than entire companies, has become the dominant playbook.

Embecta's £150 million acquisition of Owen Mumford followed the same logic: bolt-on a drug delivery platform to an existing portfolio. No transformation thesis, just asset accumulation.

On the fundraising side, Ysios Capital launched a €100 million fund dedicated to biotech startups, and Sonder Capital closed its second fund with backing from major healthcare systems. The money keeps flowing into life sciences, but it's getting more specialized.

The AI-Healthtech Wave Is Real, but Small

Five deals this week explicitly involved AI-powered healthcare. They totaled $176 million—less than 5% of the week's healthcare capital. But the breadth of applications is what matters.

Qualified Health raised $125 million in a Series B for its enterprise AI platform in healthcare. Adonis closed a $40 million Series C for AI-driven revenue cycle operations—one of the less glamorous but most commercially viable applications of machine learning in hospitals. Triangle Health raised $4 million for AI health navigation. And Spotlight Pathology secured funding for AI cancer diagnostics.

The pattern: AI in healthcare is moving from research papers to revenue. Revenue cycle management, diagnostics, clinical decision support—these are tools that pay for themselves within months, not years. Investors are noticing.

Venture Capital Dominates Deal Count, Not Dollar Volume

Of the 38 healthcare deals, 27 involved venture capital. But their combined capital was a fraction of the pharma M&A total. The median VC healthcare round this week was in the $10-20 million range—solid money, but nothing that moves a sector.

The stage distribution tells its own story. We tracked rounds from pre-seed through Series D, but the bulk of activity was concentrated at Series A. Amani Therapeutics' $25 million Series A, Dimer Health's $13.5 million round, and JAAQ's €15 million Series A in British healthtech all closed this week.

At the earliest stage, Virchow Medical raised $4 million in seed financing, while Blossom Health pulled in $20 million in combined Series A and seed funding. At the other end, Fullife Healthcare's ₹300 crore ($32 million) Series D in India showed that later-stage healthtech can still attract growth capital in emerging markets.

The Missing Middle

Here's what stood out most in this week's data: almost nothing between $50 million and $100 million. The healthcare market is splitting into two lanes. Large pharma companies spend billions acquiring proven drug programs and clinical assets. Early-stage startups raise single-digit or low-double-digit millions for AI tools, digital health platforms, and specialty therapeutics.

But the growth-stage company—the one that needs $50-150 million to scale commercially—is harder to find in this dataset. Qualified Health's $125 million Series B is one of the few exceptions, and notably, it's an enterprise AI company that happens to serve healthcare, not a pure-play biotech.

This gap matters. It suggests that the path from startup to scale in healthcare increasingly runs through acquisition, not independent growth. If you're a biotech company with a promising clinical-stage asset, the exit is a pharma buyer. If you're an AI-powered healthtech company, you scale through enterprise SaaS economics. The middle path—raising $100 million rounds to build an independent healthcare company—seems to be narrowing.

What to Watch in Q2

Three trends from this week's data are worth tracking as the second quarter approaches.

First, pharma M&A pipelines remain deep. Novartis's $2 billion deal for a single program suggests that large pharma balance sheets are actively hunting for clinical assets. Expect more targeted acquisitions in oncology, immunology, and rare disease.

Second, AI-in-healthcare is graduating from pilot to production. The deals this week funded revenue-generating tools, not research projects. That shift will accelerate as hospital systems look to cut costs heading into a more constrained reimbursement environment.

Third, healthcare-focused fund launches—Ysios's InceptionBio fund, Sonder Capital's second vehicle—indicate that institutional allocators still see healthcare and life sciences as a defensible bet. When generalist VCs pull back, specialist funds tend to fill the gap.

The $4 billion in healthcare deals this week tells two stories simultaneously: pharma's appetite for proven science is as strong as ever, and a new generation of AI-enabled healthcare startups is building the tools that might eventually disrupt how that science gets delivered. For now, those two worlds barely overlap. That could change fast.